ACADIA Pharmaceuticals Announces Election of Stephen R. Biggar to Its Board of Directors

SAN DIEGO—(BUSINESS WIRE)—Jan. 22, 2013—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical companyfocused on innovative treatments that address unmet medical needs inneurological and related central nervous system disorders, todayannounced the election of Stephen R. Biggar, M.D., Ph.D., to its boardof directors. Dr. Biggar will fill a vacancy on ACADIA’s board and serveas a Class II director. The terms of the Class II directors will expireat the annual meeting of stockholders in 2015.

“This is a particularly exciting time to join the ACADIA board followingthe highly successful results from the pivotal Phase III Parkinson’sdisease psychosis trial with pimavanserin,” said Dr. Biggar. “I share inACADIA’s enthusiasm and belief that pimavanserin has the potential totransform the treatment landscape for patients suffering from thisserious disorder and may also offer an improved therapy option for abroader range of neuropsychiatric disorders. Following the recentfinancing, which raised $86 million, ACADIA has a solid foundation forbuilding the full potential of pimavanserin. I look forward to being apart of the ACADIA team as we work to develop and commercializepimavanserin and other potential new drugs that may improve the lives ofpatients.”

Dr. Biggar serves as a Partner at Baker Brothers Investments, a fundmanagement company focused on long-term investments in life-sciencescompanies. From April 2002 to October 2006, he served as a Principalwith Baker Brothers Investments which he had joined as an Associate inApril 2000. Prior to joining Baker Brothers, Dr. Biggar received an M.D.and a Ph.D. in Immunology from Stanford University and received a B.S.in Genetics from the University of Rochester. Dr. Biggar also serves asa director for Synageva BioPharma Corp., a publicly traded biotechnologycompany.

“We are delighted that Steve has joined ACADIA’s board,” said UliHacksell, Ph.D., ACADIA’s Chief Executive Officer. “His extensiveexperience as an investor in a wide range of biotechnology companiestogether with his medical and scientific training will provide our boardwith a unique perspective and enhance our collective experience.”

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on innovative treatmentsthat address unmet medical needs in neurological and related centralnervous system disorders. ACADIA has a pipeline of product candidatesled by pimavanserin, which is in Phase III development as a potentialfirst-in-class treatment for Parkinson's disease psychosis. ACADIA alsohas clinical-stage programs for chronic pain and glaucoma incollaboration with Allergan, Inc. and two advanced preclinical programsdirected at Parkinson’s disease and other neurological disorders. Allproduct candidates are small molecules that emanate from discoveriesmade at ACADIA. ACADIA maintains a website at www.acadia-pharm.comto which ACADIA regularly posts copies of its press releases as well asadditional information and through which interested parties cansubscribe to receive email alerts.

Forward-Looking Statements

Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements related to the progress and timing of ACADIA’sdrug discovery and development programs, either alone or with a partner,and the clinical benefits to be derived from ACADIA’s productcandidates, in each case including pimavanserin. In particular,forward-looking statements include statements regarding the impact ofACADIA’s recent financing and the potential for pimavanserin totransform the treatment landscape for Parkinson’s disease psychosis andto be an improved therapy for a broader range of neuropsychiatricdisorders. These statements are only predictions based on currentinformation and expectations and involve a number of risks anduncertainties. Actual events or results may differ materially from thoseprojected in any of such statements due to various factors, includingthe risks and uncertainties inherent in drug discovery, development andcommercialization, and collaborations with others, and the fact thatpast results of clinical trials may not be indicative of future trialresults. For a discussion of these and other factors, please refer toACADIA’s annual report on Form 10-K for the year ended December 31, 2011as well as ACADIA’s subsequent filings with the Securities and ExchangeCommission. You are cautioned not to place undue reliance on theseforward-looking statements, which speak only as of the date hereof. Thiscaution is made under the safe harbor provisions of the PrivateSecurities Litigation Reform Act of 1995. All forward-looking statementsare qualified in their entirety by this cautionary statement and ACADIAundertakes no obligation to revise or update this press release toreflect events or circumstances after the date hereof, except asrequired by law.

Source: ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.
Uli Hacksell, Ph.D., ChiefExecutive Officer
Thomas H. Aasen, Executive Vice President,Chief Financial Officer and Chief Business Officer
858-558-2871